Evidence map›Paper›PMID 30902092›Full record

ArticleEnvironmental health : a global access science source2019

Urinary mycoestrogens and age and height at menarche in New Jersey girls.

Zorimar Rivera-Núñez, Emily S Barrett, Elizabeth A Szamreta, Sue A Shapses, Bo Qin, Yong Lin, Helmut Zarbl, Brian Buckley, Elisa V Bandera

Open access · goldAbstract read
In one paragraph

Article in Environmental health : a global access science source, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Mycoestrogen Exposure during Pregnancy: Impact of theEnvironmental health perspectives · 2025
    Article
  4. Article
  5. Review
  6. Endocrine-disrupting compounds and metabolomic reprogramming in breast cancer.Journal of biochemical and molecular toxicology · 2023
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Zorimar Rivera-NúñezRutgers Cancer Institute of New Jersey, 195 Little Albany St., New Brunswick, NJ, 08901, USA. zorimar.nunez@rutgers.edu.ORCID 0000-0002-0718-1807
Emily S BarrettEnvironmental and Occupational Health Sciences Institute (EOHSI), Rutgers University, 170 Frelinghuysen Rd, Piscataway, NJ, 08854, USA.
Elizabeth A SzamretaRutgers Cancer Institute of New Jersey, 195 Little Albany St., New Brunswick, NJ, 08901, USA.
Sue A ShapsesDepartment of Nutritional Sciences, Rutgers University, 65 Dudley Rd, New Brunswick, NJ, 08901-8520, USA.
Bo QinRutgers Cancer Institute of New Jersey, 195 Little Albany St., New Brunswick, NJ, 08901, USA.
Yong LinRutgers Cancer Institute of New Jersey, 195 Little Albany St., New Brunswick, NJ, 08901, USA.
Helmut ZarblRutgers Cancer Institute of New Jersey, 195 Little Albany St., New Brunswick, NJ, 08901, USA.
Brian BuckleyEnvironmental and Occupational Health Sciences Institute (EOHSI), Rutgers University, 170 Frelinghuysen Rd, Piscataway, NJ, 08854, USA.
Elisa V BanderaRutgers Cancer Institute of New Jersey, 195 Little Albany St., New Brunswick, NJ, 08901, USA.
Rutgers, The State University of New Jersey · US

Funding

TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Chang S Chan · 1997 to 2026
$94.5M
Translational Research Support CoreP30ES005022 · NIEHS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI ROBERT John LAUMBACH · 1988 to 2026
$47.4M
NCI NIH HHS P30 CA072720NIEHS NIH HHS P30 ES005022
6 · The paper itself

Abstract

backgroundDespite evidence of the endocrine disrupting properties of zearalenone (ZEN) and alpha-zearalanol (zeranol, α-ZAL), they have been minimally studied in human populations. In previous cross-sectional analyses, we demonstrated that 9-10 years old girls with detectable urinary ZEN were of shorter stature and less likely to have reached the onset of breast development than girls with undetectable urinary ZEN. The aim of this study was to examine baseline concentrations of ZEN, (α-ZAL), and their phase-1 metabolites in relation to subsequent growth and timing of menarche using 10 years of longitudinal data.

methodsUrine samples were collected from participants in the Jersey Girl Study at age 9-10 (n = 163). Unconjugated ZEN, (α-ZAL), and their metabolites were analyzed using high performance liquid chromatography and tandem mass spectrometry. Information on height, weight, and pubertal development was collected at a baseline visit with annual follow-up by mail thereafter. Cox regression was used to evaluate time to menarche in relation to baseline ZEN, (α-ZAL), and total mycoestrogen exposure. Z-scores for height and weight were used in mixed models to assess growth.

resultsMycoestrogens were detectable in urine in 78.5% of the girls (median ZEN: 1.02 ng/ml, range 0-22.3). Girls with detectable urinary concentrations of (α-ZAL) and total mycoestrogens (sum of ZEN, (α-ZAL) and their metabolites) at baseline were significantly shorter at menarche than girls with levels below detection (p = 0.04). ZEN and total mycoestrogen concentrations were inversely associated with height- and weight-z-scores at menarche (adjusted β = - 0.18, 95% CI: -0.29, - 0.08, and adjusted β = - 0.10, 95% CI: -0.21, 0.01, respectively).

conclusionThis study supports and extends our previous results suggesting that exposure to ZEN, (α-ZAL), and their metabolites is associated with slower growth and pubertal development in adolescent girls.

Indexed as

Sexual DevelopmentBody HeightBody WeightChildEndocrine DisruptorsEnvironmental MonitoringEstrogensFemaleHumansNew JerseyZearalenoneZeranolEndocrine DisruptorsEstrogensZearalenoneZeranolEndocrine disruptorsMycoestrogensPubertyZearalenone(α-ZAL)

Identifiers

PMID30902092
PMCPMC6431018
OpenAlexW2942647510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.